Announcements Trials
Browse Landscape

Phase

Phase 2 31Phase 1 16Phase 3 7Phase 1/2 5Phase NA 2Phase 4 1Phase 2/3 1

Status

Completed 23Recruiting 14Unknown 6Terminated 5Withdrawn 3Not yet recruiting 2Active not recruiting 2Suspended 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 123Breast Neoplasms 103Neoplasms 100Leukemia, Myeloid, Acute 88Melanoma 86Multiple Myeloma 81Neoplasm Metastasis 80Recurrence 68Ovarian Neoplasms 65Prostatic Neoplasms 59Lymphoma 59Colorectal Neoplasms 58Lymphoma, Non-Hodgkin 55Leukemia 55Pancreatic Neoplasms 50Lung Neoplasms 48Myelodysplastic Syndromes 42Leukemia, Lymphocytic, Chronic, B-Cell 42Carcinoma, Renal Cell 39Squamous Cell Carcinoma of Head and Neck 38Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Glioblastoma 35Lymphoma, Large B-Cell, Diffuse 34Carcinoma, Hepatocellular 33Triple Negative Breast Neoplasms 32Stomach Neoplasms 29Small Cell Lung Carcinoma 27Lymphoma, Follicular 27Brain Neoplasms 26Lymphoma, Mantle-Cell 25

Interventions

regorafenib 1olaparib 1Taxes 1Prednisone 1Paclitaxel 1Irinotecan 1Gemcitabine 1Everolimus 1Carboplatin 1Capecitabine 1Albumin-Bound Paclitaxel 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Adenocarcinoma × Clear all
NCT04556617 2025-04-08

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Opna Bio LLC

Phase 1/2 Terminated
19 enrolled 11 charts
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT04983407 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Aravive, Inc.

Phase 1/2 Terminated
34 enrolled

Adenocarcinoma, Neoplasm Metastasis, Recurrence

NCT03722108 2023-10-16

REGIRI

UNICANCER

Phase 1/2 Terminated
89 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT01784861 2021-07-08

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

Washington University School of Medicine

Phase 1/2 Terminated
23 enrolled 17 charts
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT00201734 2016-09-23

Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
57 enrolled 11 charts
Tumor-Agnostic

Adenocarcinoma, Neoplasms, Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡